Suchergebnisse - "Wei, Xing"

PubPharm (31)

1

B-Myb deficiency boosts bortezomib-induced immunogenic cell death in colorectal cancer

enthalten in: Scientific reports | 2024

von Hui, Y. | Yu, T. | Li, L. | +7

2

Four previously undescribed diketopiperazines from marine fungus Aspergillus puniceus FAHY0085 and their effects on liver X receptor α

enthalten in: Phytochemistry | 2023

von Hong, Q. | Guo, M. | Yang, J. | +5

3

Antitumor effects of new glycoconjugated PtII agents dual-targeting GLUT1 and Pgp proteins

enthalten in: Dalton transactions (Cambridge, England : 2003) | 2022

von Zhang, Q. | Shao, J. | Wang, J. | +8

4

Ursolic acid represses influenza A virus-triggered inflammation and oxidative stress in A549 cells by modulating the miR-34c-5p/TLR5 axis

enthalten in: Cytokine | 2022

von Wei, X. | Lan, Y. | Nong, Z. | +5

5

Optimization of Beclin 1-Targeting Stapled Peptides by Staple Scanning Leads to Enhanced Antiproliferative Potency in Cancer Cells

enthalten in: Journal of medicinal chemistry | 2021

von Yang, Q. | Qiu, X. | Zhang, X. | +7

6

Loss of TRIM21 alleviates cardiotoxicity by suppressing ferroptosis induced by the chemotherapeutic agent doxorubicin

enthalten in: EBioMedicine | 2021

von Hou, K. | Shen, J. | Yan, J. | +10

7

System Analysis of ROS-Related Genes in the Prognosis, Immune Infiltration, and Drug Sensitivity in Hepatocellular Carcinoma

enthalten in: Oxidative medicine and cellular longevity | 2021

von Xu, J. | Guan, Y. | Qiu, Z. | +7

ErratumIn: Oxid Med Cell Longev. 2022 Feb 21;2022:9875295. - PMID 35237387

8

Study on efficacy and safety of Huangqi Guizhi Wuwu decoction treatment for oxaliplatin induced peripheral neurotoxicity : A protocol for a randomized, controlled, double-blind, multicenter trial

enthalten in: Medicine | 2020

von Wei, X. | Chen, X. | Shu, P. | +14

9

PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers

enthalten in: Molecular cancer therapeutics | 2020

von Zhang, Z. | Yu, W. | Zheng, M. | +9

ErratumIn: Mol Cancer Ther. 2024 May 2;23(5):743. - PMID 38693904

10

Postoperative adjuvant sorafenib improves survival outcomes in hepatocellular carcinoma patients with microvascular invasion after R0 liver resection : a propensity score matching analysis

enthalten in: HPB : the official journal of the International Hepato Pancreato Biliary Association | 2019

von Zhang, X. | Chai, Z. | Gao, Y. | +10